Minireviews
Copyright ©The Author(s) 2021.
World J Gastrointest Surg. Aug 27, 2021; 13(8): 756-763
Published online Aug 27, 2021. doi: 10.4240/wjgs.v13.i8.756
Table 1 Definition and treatment strategy for borderline resectable colorectal liver metastases in previous studies
Ref.
Definition
Treatment
Prognosis
Jones et al[44], 2013Synchronous (< 12 mo); Bilobar diseases: Number ≥ 4; Size ≥ 5 cm; CEA ≥ 100 ng/mLNAC (FOLFOX)-
Worni et al[45], 2014Bilobar diseases; Proximity to vascular or biliary structure; Low FLRNAC-
Qadan et al[3], 2015Low FLR (< 20%, < 2 contiguous segments); Extrahepatic diseases; R1: Number ≥ 4NAC (doublet or triplet)-
Kaczirek et al[42], 2017-NAC (doublet + bevacizumab)-
Phelip et al[49], 20163 ≤ Number < 8; ≤ 6 segments involvement; Without infiltration of HA, HV, and PV; Extrahepatic diseases ≤ 2NAC (FOLFIRI)3-yr PFS: 23.3%; 3-yr OS: 66.1%
Van Cutsem et al[43], 2016Extrahepatic diseases: Number ≥ 5; Tumor progressionNAC (doublet or triplet)-
Pietrantonio et al[46], 2017> 1 hepatic vein involvement; > 4 segments involvement; Necessity of RFA or TSH; Number ≥ 4; SynchronousPre/post 4 cycle chemotherapy (COI-E)Median PFS 17.8 mo; Median OS 62.5 mo
Bonadio et al[47], 2019Number ≥ 4; Proximity to vascular or biliary structureNAC (mFLOX)Median PFS 16.9 mo; Median OS 68.3 mo
Ichida et al[48], 2019Number ≥ 4; Size ≥ 5 cm; Extrahepatic diseasesNAC (doublet)BR-NAC vs resectable: 5-yr RFS: 22.1% vs 46.5%, P = 0.02; 5-yr OS: 66.6% vs 74.0%, P = 0.40